The translocator protein (18 kDa): Central nervous system disease and drug design

Journal of Medicinal Chemistry

Volumn 52, Issue 3, 2009, Pages 581-592

  Scarf, Alana M ^a,b   Ittner, Lars M ^a   Kassiou, Michael ^a,c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETAMIDE DERIVATIVE; AMIDE; BENZODIAZEPINE RECEPTOR; CARRIER PROTEIN; DAA 1097; DAA 1106; DIAZEPAM BINDING INHIBITOR; DIAZEPAM DERIVATIVE; DPA 713; DPA 714; FGIN 127; INDOLEACETIC ACID DERIVATIVE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PYRAZOLOPYRIMIDINE DERIVATIVE; RO 54864; SSR 180575; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR; DIPHENYL ETHER DERIVATIVE; INDOLE DERIVATIVE; INDOLEACETAMIDE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TSPO PROTEIN, HUMAN;

ALZHEIMER DISEASE; AUTORADIOGRAPHY; BINDING SITE; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM DISEASE; DOWN REGULATION; DRUG DESIGN; HUMAN; HUNTINGTON CHOREA; ISOTOPE LABELING; LIGAND BINDING; MAJOR DEPRESSION; MITOCHONDRIAL MEMBRANE; MOLECULAR WEIGHT; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; STEROIDOGENESIS; APOPTOSIS; CENTRAL NERVOUS SYSTEM; CHEMISTRY; DEGENERATIVE DISEASE; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACETAMIDES; APOPTOSIS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; HUMANS; INDOLEACETIC ACIDS; INDOLES; MITOCHONDRIAL MEMBRANES; NEURODEGENERATIVE DISEASES; PHENYL ETHERS; PYRAZOLES; PYRIMIDINES; RECEPTORS, GABA;

EID: 61449203017     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8011678     Document Type: Review

References (113)

1. Chebib, M.; Johnson, G. GABA-activated ligand gated ion channels: medicinal chemistry and molecular biology. J. Med. Chem. 2000, 43, 1427-1447.
2. Johnson, G.; Hanrahan, J.; Chebib, M.; Duke, R.; Mewett, K. Modulation of ionotropic GABA receptors by natural products of plant origin. Adv. Pharmacol. 2006, 54, 235-316.
3. Costa, E.; Guidotti, A. Molecular mechanisms in the receptor action of benzodiazepines. Annu. Rev. Pharmacol. Toxicol. 1979, 19, 531-545.
4. 3H]diazepam binding. Proc. Natl. Acad. Sci. U.S.A. 1977, 74, 3805-3809.
5. Syapin, P. J.; Skolnick, P. Characterisation of benzodiazepine binding sites in cultured cells of neural origin. J. Neurochem. 1979, 32, 1047-1051.
6. Benavides, J.; Fage, D.; Carter, C.; Scatton, B. Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage. Brain Res. 1987, 421, 167-172.
7. Costa, E.; Auta, J.; Guidotti, A.; Korneyev, A.; Romeo, E. The pharmacology of neurosteroidogenesis. J. Steroid Biochem. Mol. Biol. 1994, 49, 385-389.
8. James, M.; Selleri, S.; Kassiou, M. Development of ligands for the peripheral benzodiazepine receptor. Curr. Med. Chem. 2006, 13, 1991-2001.
9. Papadopoulos, V. Peripheral-type benzodiazepine/diazepam binding inhibitor receptor: biological role in steroidogenic cell function. Endocr. Rev. 1993, 14, 222-240.
10. Verma, A.; Nye, J. S.; Solomon, H. S. Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 2256-2260.
11. Verma, A.; Snyder, S. Characterization of porphyrin interactions with peripheral type benzodiazepine receptors. Mol. Pharmacol. 1988, 34, 800-805.
12. Wendler, G.; Lindemann, P.; Lacapère, J.-J.; Papadopoulos, V. Protoporphyrin IX binding and transport by recombinant mouse PBR. Biochem. Biophys. Res. Commun. 2003, 311, 847-852.
13. Papadopoulos, V.; Baraldi, M.; Guilarte, T. R.; Knudsen, T.; Lacapere, J.; Lindemann, P.; Norenberg, M. D.; Nutt, D.; Weizman, A.; Zhang, M.; Gavish, M. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 2006, 27, 402-409.
14. 3H]PK11195 to cerebral cortex and peripheral tissues of various species: species differences and heterogeneity in peripheral benzodiazepine binding sites. J. Neurochem. 1987, 49, 1407-1414.
15. 3H]PK11195, by thermodynamic studies. Life Sci. 1983, 33, 449-457.
16. Braestrup, C.; Nielsen, M.; Squires, R.; Laurberg, S. Benzodiazepine receptor in brain. Acta Psychiatr. Scand. 1978, 58, 27-32.
17. Schoemaker, H.; Boles, R.; Horst, W.; Yamamura, H. Specific high- affinity binding sites for [3H]Ro 5-4864 in rat brain and kidney. J. Pharmacol. Exp. Ther. 1983, 225, 61-69.
18. Borea, P.; Gilli, G.; Bertolasi, V.; Ferretti, V. Stereochemical features controlling binding and intrinsic activity properties of benzodiazepine receptor ligands. Mol. Pharmacol. 1986, 31, 334-344.
19. Anholt, R.; Pedersen, P.; De Souza, E.; Snyder, S. The peripheral type benzodiazepine receptor. Localization to the mitochondrial outer membrane. J. Biol. Chem. 1986, 261, 576-583.
20. Lacapere, J.-J.; Papadopoulos, V. Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis. Steroids 2003, 68, 569-585.
21. Garnier, M.; Boujrad, N.; Oke, B.; Brown, A.; Riond, J.; Ferrara, P.; Shoyab, M.; Suarez-Quian, C.; Papadopoulos, V. Diazepam binding inhibitor is a paracrine/autocrine regulator of leydig cell proliferation and steroidogenesis: action via peripheral-type benzo- diazepine receptor and independent mechanisms. Endocrinology 1993, 132, 444-458.
22. Canat, X.; Carayon, P.; Bouaboula, M.; Cahard, D.; Shire, D.; Roque, C.; Le Fur, G.; Casellas, P. Distribution profile and properties of peripheral-type benzodiazepine receptors on human hemopoietic cells. Life Sci. 1993, 52, 107-118.
23. Cahard, D.; Canat, X.; Carayon, P.; Roque, C.; Casellas, P.; Le Fur, G. Subcellular localization of peripheral benzodiazepine receptors on human leukocytes. Lab. Invest. 1994, 70, 23-28.
24. Lang, S. The role of peripheral benzodiazepine receptors (PBRs) in CNS pathophysiology. Curr. Med. Chem. 2002, 9, 1411-1415.
25. Wilms, H.; Claasen, J.; Rohl, C.; Sievers, J.; Deuschl, G.; Lucius, R. Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro. Neurobiol. Dis. 2003, 14, 417-424.
26. Joseph-Liauzun, E.; Delmas, P.; Shire, D.; Ferrara, P. Topological analysis of the peripheral benzodiazepine receptor in yeast mitochondrial membranes supports a five-transmembrane structure. J. Biol. Chem. 1998, 273, 2146-2152.
27. Bernassau, J.; Reversat, J.; Ferrara, P.; Caput, D.; Le Fur, G. A 3d model of the peripheral benzodiazepine receptor and its implication in intra mitochondrial cholesterol transport. J. Mol. Graphics 1993, 11, 236-244.
28. Murail, S.; Robert, J.-C.; Coïc, Y.-M.; Neumann, J.-M.; Ostuni, M. A.; Yao, Z.-X.; Papadopoulos, V.; Jamin, N.; Lacapère, J.-J. Secondary and tertiary structures of the transmembrane domains of the translocator protein TSPO determined by NMR. Stabilization of the TSPO tertiary fold upon ligand binding. Biochim. Biophys. Acta 2008, 1778, 1375-1381.
29. Boujrad, N.; Vidic, B.; Papadopoulos, V. Acute action of choriogonadotropin on Leydig tumor cells: changes in the topography of the mitochondrial peripheral-type benzodiazepine receptor. Endocrinology 1996, 137, 5727-5730.
30. McEnery, M.; Snowman, A.; Trifiletti, R.; Snyder, S. Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 3170-3174.
31. Moran, O.; Sandri, G.; Panfili, E.; Stuhmer, W.; Sorgato, M. C. Electrophysiological characterization of contact sites in brain mitochondria. J. Biol. Chem. 1990, 265, 908-913 (published erratum appears in J. Biol. Chem. 1990, 265 (19, July 5), 11405.
32. Joseph-Liauzun, E.; Farges, R.; Delmas, P.; Ferrara, P.; Loison, G. The mr 18,000 subunit of the peripheral-type benzodiazepine receptor exhibits both benzodiazepine and isoquinoline carboxamide binding sites in the absence of the voltage-dependent anion channel or of the adenine nucleotide carrier. J. Biol. Chem. 1997, 272, 28102-28106.
33. Galiegue, S.; Jbilo, O.; Combes, T.; Bribes, E.; Carayon, P.; Le Fur, G.; Casellas, P. Cloning and characterization of PRAX-1. A new protein that specifically interacts with the peripheral benzodiazepine receptor. J. Biol. Chem. 1999, 274, 2938-2952.
34. Yeliseev, A. A.; Kaplan, S. Tspo of rhodobacter sphaeroides. A structural and functional model for the mammalian peripheral benzodiazepine receptor. J. Biol. Chem. 2000, 275, 5657-5667.
35. Papadopoulos, V.; Brown, A. S. Role of the peripheral-type benzodiazepine receptor and the polypeptide diazepam binding inhibitor in steroidogenesis. J. Steroid Biochem. Mol. Biol. 1995, 53, 103-110.
36. Papadopoulos, V.; Amri, H.; Li, H.; Boujrad, N.; Vidic, B.; Garnier, M. Targeted disruption of the peripheral-type benzodiazepine receptor gene inhibits steroidogenesis in the R2C Leydig tumor cell line. J. Biol. Chem. 1997, 272, 32129-32135.
37. Besman, M.; Yanagibashi, K.; Lee, T.; Kawamura, M.; Hall, P.; Shively, J. Identification of des-(gly-ile)-endozepine as an effector of corticotropin-dependent adrenal steroidogenesis: stimulation of cholesterol delivery is mediated by the peripheral benzodiazepine receptor. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 4897-4901.
38. Jamin, N.; Neumann, J.-M.; Ostuni, M. A.; Vu, T. K. N.; Yao, Z. X.; Murail, S.; Robert, J.-C.; Giatzakis, C.; Papadopoulos, V.; Lacapere, J.-J. Characterization of the cholesterol recognition amino acid consensus sequence of the peripheral-type benzodiazepine receptor. Mol. Endocrinol. 2005, 19, 588-594.
39. Veenman, L.; Papadopoulos, V.; Gavish, M. Channel-like functions of the 18 kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defence response. Curr. Pharm. Des. 2007, 13, 2385-2405.
40. Galiegue, S.; Jbilo, O.; Combes, T.; Bribes, E.; Carayon, P.; Le Fur, G.; Casellas, P. Cloning and characterization of PRAX-1. A new protein that specifically interacts with the peripheral benzodiazepine receptor. J. Biol. Chem. 1999, 274, 2938-2952.
41. Raid, M.; Mogos, M.; Thangathurai, D.; Lumb, P. Steroids. Curr. Opin. Crit. Care 2002, 8, 281-284.
42. Kunduzova, O.; Escourrou, G.; De La Farge, F.; Salvayre, R.; Seguelas, M.-H.; Leducq, N.; Bono, F.; Herbert, J.-M.; Parini, A. Involvement of peripheral benzodiazepine receptor in the oxidative stress, death-signaling pathways, and renal injury induced by ischemia-reperfusion. J. Am. Soc. Nephrol. 2004, 15, 2152-2160.
43. Halestrap, A.; Doran, E.; Gillespie, J.; O'Toole, A. Mitochondria and cell death. Biochem. Soc. Trans. 2000, 28, 170-177.
44. Casellas, P.; Galiegue, S.; Basile, A. S. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem. Int. 2002, 40,475-486.
45. Li, W.; Hardwick, M. J.; Rosenthal, D.; Culty, M.; Papadopoulos, V. Peripheral-type benzodiazepine receptor overexpression and knockdown in human breast cancer cells indicate its prominent role in tumor cell proliferation. Biochem. Pharmacol. 2007, 73, 491-503.
46. Hirsch, T.; Decaudin, D.; Susin, S. A.; Marchetti, P.; Larochette, N.; Resche-Rigon, M.; Kroemer, G. PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection. Exp. Cell Res. 1998, 241, 426-434.
47. Pastorino, J. G.; Simbula, G.; Yamamoto, K.; Glascott, P. A., Jr.; Rothman, R. J.; Farber, J. L. The cytotoxicity of tumor necrosis factor depends on induction of the mitochondrial permeability transition. J. Biol. Chem. 1996, 271, 29792-29798.
48. Decaudin, D.; Castedo, M.; Nemati, F.; Beurdeley-Thomas, A.; De Pinieux, G.; Caron, A.; Pouillart, P.; Wijdenes, J.; Rouillard, D.; Kroemer, G.; Poupon, M.-F. Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res. 2002, 62, 1388-1393.
49. Hans, G.; Wislet-Gendebien, S.; Lallemend, F.; Robe, P.; Rogister, B.; Belachew, S.; Nguyen, L.; Malgrange, B.; Moonen, G.; Rigo, J.-M. Peripheral benzodiazepine receptor (PBR) ligand cytotoxicity unrelated to PBR expression. Biochem. Pharmacol. 2005, 69, 819-830.
50. Bono, F.; Lamarche, I.; Prabonnaud, V.; Le Fur, G.; Herbert, J. Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities. Biochem. Biophys. Res. Commun. 1999, 265, 457-461.
51. Zavala, F.; Taupin, V.; Descamps-Latscha, B. In vivo treatment with benzodiazepines inhibits murine phagocyte oxidative metabolism and production of interleukin 1, tumor necrosis factor and interleukin-6. J. Pharmacol. Exp. Ther. 1990, 255, 442-450.
52. Zavala, F.; Veber, F.; Taupin, V.; Nguyen, A.; Descamps-Latscha, B. A physiological role for the peripheral benzodiazepine receptor on human neutrophils. Ann. N.Y. Acad. Sci. 1992, 650, 229-233.
53. Versijpt, J.; Dumont, F.; Van Laere, K.; Decoo, D.; Santens, P.; Audenaert, K.; Achten, E.; Slegers, G.; Dierckx, R.; Korf, J. Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. Eur. Neurol. 2003, 50, 39-47.
54. 2+]i responses in human microglia by the peripheral benzodiazepine receptor ligand PK11195. J. Neuro chem. 2002, 83, 546-555.
55. Kreutzberg, G. W. Microglia: a sensor for pathological events in the cns. Trends Neurosci. 1996, 19, 312-318.
56. Liu, B.; Wang, K.; Gao, H.-M.; Mandavilli, B.; Wang, J.-Y.; Hong, J.-S. Molecular consequences of activated microglia in the brain: overactivation induces apoptosis. J. Neurochem. 2001, 77, 182-189.
57. Banati, R.; Gehrmann, J.; Schubert, P.; Kreutzberg, G. Cytotoxicity of microglia. Glia 1993, 7, 111-118.
58. 11C]DAA1106 for PET: an imaging tool for glial cells in the brain. Synapse 2004, 52, 283-291.
59. Okuyama, S.; Chaki, S.; Yoshikawa, R.; Ogawa, S.-i.; Suzuki, Y.; Okubo, T.; Nakazato, A.; Nagamine, M.; Tomisawa, K. Neuropharmacological profile of peripheral benzodiazepine receptor agonists, DAA1097 and DAA1106. Life Sci. 1999, 64, 1455-1464.
60. Culty, M.; Silver, P.; Nakazato, A.; Gazouli, M.; Li, H.; Maramatsu, M.; Okuyama, S.; Papadopoulos, V. Peripheral benzodiazepine receptor binding properties and effects on steroid synthesis of two new phenoxyphenyl-acetamide derivatives, DAA1097 and DAA1106. Drug Dev. Res. 2001, 52, 475-484.
61. Romeo, E.; Cavallaro, S.; Korneyev, A.; Kozikowski, A. P.; Ma, D.; Polo, A.; Costa, E.; Guidotti, A. Stimulation of brain steroido- genesis by 2-aryl-indole-3-acetamide derivatives acting at the mito- chondrial diazepam-binding inhibitor receptor complex. J. Pharmacol. Exp. Ther. 1993, 267, 462-471.
62. Vin, V.; Leducq, N.; Bono, F.; Herbert, J. M. Binding characteristics of ssr180575, a potent and selective peripheral benzodiazepine ligand. Biochem. Biophys. Res. Commun. 2003, 310, 785-790.
63. Ferzaz, B.; Brault, E.; Bourliaud, G.; Robert, J.-P.; Poughon, G.; Claustre, Y.; Marguet, F.; Liere, P.; Schumacher, M.; Nowicki, J.- P.; Fournier, J.; Marabout, B.; Sevrin, M.; George, P.; Soubrie, P.; Benavides, J.; Scatton, B. SSR180575 (7-chloro-N,N,5-trimethyl-4- oxo-3-phenyl-3,5-dihydro-4//- pyridazino[4,5-Z;]indole-1-aceta- mide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair. J. Pharmacol. Exp. Ther. 2002, 301, 1067-1078.
64. Selleri, S.; Bruni, F.; Costagli, C.; Costanzo, A.; Guerrini, G.; Ciciani, G.; Costa, B.; Martini, C. 2-Arylpyrazolo[1,5-a]pyrimidin-3-yl ac- etamides. New potent and selective peripheral benzodiazepine receptor ligands. Bioorg. Med. Chem. 2001, 9, 2661-2671.
65. Anzini, M.; Cappelli, A.; Vomero, S.; Seeber, M.; Menziani, M.; Langer, T.; Hagen, B.; Manzoni, C.; Bourguignon, J.-J. Mapping and fitting the peripheral benzodiazepine receptor binding site by carboxamide derivatives. Comparison of different approaches to quantitative ligand- receptor interaction modeling. J. Med. Chem. 2001, 44, 1134-1150.
66. James, M. L.; Fulton, R. R.; Vercoullie, J.; Henderson, D. J.; Garreau, L.; Chalon, S.; Dolle, F.; Costa, B.; Guilloteau, D.; Kassiou, M. DPA714, a new translocator protein-specific ligand: synthesis, radioflu- orination, and pharmacologic characterization. J. Nucl. Med. 2008, 49, 814-822.
67. James, M. L.; Fulton, R. R.; Henderson, D. J.; Eberl, S.; Meikle, S. R.; Thomson, S.; Allan, R. D.; Dolle, F.; Fulham, M. J.; Kassiou, M. Synthesis and in vivo evaluation of a novel peripheral benzodi- azepine receptor PET radioligand. Bioorg. Med. Chem. 2005, 13, 6188-6194.
68. Da Settimo, F.; Simorini, F.; Taliani, S.; La Motta, C.; Marini, A.; Salerno, S.; Bellandi, M.; Novellino, E.; Greco, G.; Cosimelli, B.; Da Pozzo, E.; Costa, B.; Simola, N.; Morelli, M.; Martini, C. Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxyla- mides by modulation of translocator protein promoting neurosteroid biosynthesis. J. Med. Chem. 2008, 51, 5789-5797.
69. Banati, R. B.; Egensperger, R.; Maassen, A.; Hager, G.; Kreutzberg, G. W.; Graeber, M. B. Mitochondria in activated microglia in vitro. J. Neurocytol. 2004, 33, 535-541.
70. Cagnin, A.; Rossor, M.; Sampson, E.; MacKinnon, T.; Banati, R. In vivo detection of microglial activation in frontotemporal dementia. Ann. Neurol. 2004, 56, 894-897.
71. Ramsay, S. C.; Weiller, C.; Myers, R.; Cremer, J. E.; Luthra, S. K.; Lammertsma, A. A.; Frackowiak, R. S. J. Monitoring by pet of macrophage accumulation in brain after ischaemic stroke. Lancet 1992, 339, 1054-1055.
72. 11C]-PK11195 and positron emission tomography in patients after ischemic stroke. NeuroReport 2000, 11, 2957-2960.
73. Chen, M.-K.; Guilarte, T. R. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair. Pharmacol. Ther. 2008, 118, 1-17.
74. Guilarte, T.; Kuhlmann, A.; O'Callaghan, J.; Miceli, R. Enchanced expression of peripheral benzoidazepine receptors in trimethyltinexposed rat brain: a biomarker of neurotoxicity. Neurotoxicology 1995, 16, 441-450.
75. Pavese, N.; Gerhard, A.; Tai, Y. F.; Ho, A. K.; Turkheimer, F.; Barker, R. A.; Brooks, D. J.; Piccini, P. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006, 66, 1638-1643.
76. Banati, R.; Newcombe, J.; Gunn, R.; Cagnin, A.; Turkheimer, F.; Heppner, F.; Price, G.; Wegner, F.; Giovannoni, G.; Miller, D.; Perkin, G.; Smith, T.; Hewson, A.; Bydder, G.; Kreutzberg, G.; Jones, T.; Cuzner, M.; Myers, R. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging ofmicroglia as a measure ofdisease activity. Brain 2000, 123, 2321-2337.
77. Venneti, S.; Wang, G.; Wiley, C. A. Activated macrophages in HIV encephalitis and a macaque model show increased [3H](R)-PK11195 binding in a pi3-kinase-dependent manner. Neurosci. Lett. 2007, 426, 117-122.
78. 3H]Ro5-4864 benzodiazepine binding in the kainate lesioned striatum and Huntington's diseased basal ganglia. Brain Res. 1982, 248, 396-401.
79. 3H]PK11195 binding autoradiography. Exp. Neurol. 1990, 109, 333-341.
80. Agnello, D.; Carvelli, L.; Muzio, V.; Villa, P.; Bottazzi, B.; Polentarutti, N.; Mennini, T.; Mantovani, A.; Ghezzi, P. Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory cytokines and modulation by dexamethasone and rolipram. J. Neuroimmunol. 2000, 109, 105-111.
81. Vowinckel, E.; Reutens, D.; Becher, B.; Verge, G.; Evans, A.; Owens, T.; Antel, J. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J. Neurosci. Res. 1997, 50, 345-353.
82. Mattner, F.; Katsifis, A.; Staykova, M.; Ballantyne, P.; Willenborg, D. O. Evaluation of a radiolabelled peripheral benzodiazepine receptor ligand in the central nervous system inflammation of experimental autoimmune encephalomyelitis: a possible probe for imaging multiple sclerosis. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 557-563.
83. Messmer, K.; Reynolds, G. P. Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease. Neurosci. Lett. 1998, 241, 53-56.
84. Gulyás, B.; Makkai, B.; Kása, P.; Gulya, K.; Bakota, L.; Varszegi, S.; Beliczai, Z.; Andersson, J.; Csiba, L.; Thiele, A.; Dyrks, T.; Suhara, T.; Suzuki, K.; Higuchi, M.; Halldin, C. A comparative autoradiography study in post mortem whole hemisphere human brain slices taken from Alzheimer patients and age-matched controls using two radiolabelled DAA1106 analogues with high affinity to the peripheral benzodiazepine receptor (PBR) system. Neurochem. Int., in press. (85) Venneti, S.; Lopresti, B. J.; Wiley, C. A. The peripheral benzodi- azepine receptor (translocator protein 18 kDa) in microglia: from pathology to imaging. Prog. Neurobiol. 2006, 80, 308-322.
85. Lacor, P.; Benavides, J.; Ferzaz, B. Enhanced expression of the peripheral benzodiazepine receptor (PBR) and its endogenous ligand octadecaneuropeptide (ODN) in the regenerating adult rat sciatic nerve. Neurosci. Lett. 1996, 220, 61-65.
86. 11C]PK11195. Eur. J. Neurol. 2003, 10, 257-264.
87. 11C]DAA1106. Biol. Psychiatry, in press.
88. Chen, M.-K.; Kuwabara, H.; Zhou, Y.; Adams, R. J.; Brasic, J. R.; McGlothan, J. L.; Verina, T.; Burton, N. C.; Alexander, M.; Kumar, A.; Wong, D. F.; Guilarte, T. R. VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J. Neurochem. 2008, 105, 78-90.
89. 11C](R)-PK11195 pet in idiopathic Parkinson's disease. Neurobiol. Dis. 2006, 21, 404-412.
90. Belloli, S.; Moresco, R. M.; Matarrese, M.; Biella, G.; Sanvito, F.; Simonelli, P.; Turolla, E.; Olivieri, S.; Cappelli, A.; Vomero, S.; GalliKienle, M.; Fazio, F. Evaluation of three quinoline-carboxamide derivatives as potential radioligands for the in vivo pet imaging of neurodegeneration. Neurochem. Int. 2004, 44, 433-440.
91. Ryu, J. K.; Choi, H. B.; McLarnon, J. G. Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum. Neurobiol. Dis. 2005, 20, 550-561.
92. Matsumoto, T.; Ogata, M.; Koga, K.; Shigematsu, A. Effect of peripheral benzodiazepine receptor ligands on lipopolysaccharide induced tumor necrosis factor activity in thioglycolate-treated mice. Antimicrob. Agents Chemother. 1994, 34, 812-816.
93. Veiga, S.; Carrero, P.; Pernia, S.; Azcoitia, I.; Garcia-Segura, L. Translocator protein (18 kDa) is involved in the regulation of reactive gliosis. Glia 2007, 55, 1426-1436.
94. Alexi, T.; Borlongan, C. V.; Faull, R. L. M.; Williams, C. E.; Clark, R. G.; Gluckman, P. D.; Hughes, P. E. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog. Neurobiol. 2000, 60, 409-470.
95. Blandini, F.; Cosentino, M.; Mangiagalli, A.; Marino, F.; Samuele, A.; Rasini, E.; Fancellu, R.; Tassorelli, C.; Pacchetti, C.; Martignoni, E.; Riboldazzi, G.; Calandrella, D.; Lecchini, S.; Frigo, G.; Nappi, G. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. J. Neural Transm. 2004, 111, 1017-1030.
96. Lacor, P.; Gandolfo, P.; Tonon, M.-C.; Brault, E.; Dalibert, I.; Schumacher, M.; Benavides, J.; Ferzaz, B. Regulation of the expression of peripheral benzodiazepine receptors and their endogenous ligands during rat sciatic nerve degeneration and regeneration: a role for PBR in neurosteroidogenesis. Brain Res. 1999, 815, 70-80.
97. Koenig, H.; Schumacher, M.; Ferzaz, B.; Thi, A.; Ressouches, A.; Guennoun, R.; Jung-Testas, I.; Robel, P.; Akwa, Y.; Baulieu, E.-E. Progesterone synthesis and myelin formation by Schwann cells. Obstet. Gynecol. Surv. 1995, 50, 792-793.
98. Ritsner, M.; Modai, I.; Gibel, A.; Leschiner, S.; Silver, H.; Tsinovoy, G.; Weizman, A.; Gavish, M. Decreased platelet peripheral-type benzodiazepine receptors in persistently violent schizophrenia patients. J. Psychiatr. Res. 2003, 37, 549-556.
99. Nicolas, L. B.; Pinoteau, W.; Papot, S.; Routier, S.; Guillaumet, G.; Mortaud, S. Aggressive behavior induced by the steroid sulfatase inhibitor coumate and by DHEAS in cba/h mice. Brain Res. 2001, 922, 216-222.
100. Mandel, P.; Mack, G.; Kempf, E. Molecular Basis of Some Models of Aggressive Behavior. In Psychopharmacology of Aggression; Sandler, M., Ed.; Raven Press: New York, 1979; pp 95-110.
101. Auta, J.; Romeo, E.; Kozikowski, A.; Ma, D.; Costa, E.; Guidotti, A. Participation of mitochondrial diazepam binding inhibitor receptors in the anticonflict, antineophobic and anticonvulsant action of 2-aryl- 3-indoleacetamide and imidazopyridine derivatives. J. Pharmacol. Exp. Ther. 1993, 265, 649-656.
102. Weizman, R.; Tanne, Z.; Granek, M.; Karp, L.; Golomb, M.; Tyano, S.; Gavish, M. Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients. Eur. J. Pharmacol. 1987, 138, 289-292.
103. Ferrarese, C.; Appollonio, I.; Frigo, M.; Perego, M.; Piolti, R.; Trabucchi, M.; Frattola, L. Decreased density of benzodiazepine receptors in lymphocytes of anxious patients: reversal after chronic diazepam treatment. Acta Psychiatr. Scand. 1990, 82, 169-173.
104. Gavish, M.; Katz, Y.; Bar-Ami, S.; Weizman, R. Biochemical, physiological, and pathological aspects of the peripheral benzodiaz- epine receptor. J. Neurochem. 1992, 58, 1589-1601.
105. Benavides, J.; Begassat, F.; Phan, T.; Tur, C.; Uzan, A.; Renault, C.; Dubroeucq, M.; Gueremy, C.; Le Fur, G. Histidine modification with diethylpyrocarbonate induces a decrease in the binding of an antagonist, PK11195, but not of an agonist, Ro5-4864, of the peripheral benzodiazepine receptors. Life Sci. 1984, 35, 1249-1256.
106. Skowronski, R.; Beaumont, K.; Fanestil, D. D. Modification of the peripheral-type benzodiazepine receptor by arachidonate, diethylpy- rocarbonate and thiol reagents. Eur. J. Pharmacol. 1987, 143, 305-314.
107. Farges, R.; Joseph-Liauzun, E.; Shire, D.; Caput, D.; Le Fur, G.; Ferrara, P. Site-directed mutagenesis of the peripheral benzodiazepine receptor: identification of amino acids implicated in the binding site of Ro5-4864. Mol. Pharmacol. 1994, 46, 1160-1167.
108. Lockhart, A.; Davis, B.; Matthews, J. C.; Rahmoune, H.; Hong, G.; Gee, A.; Earnshaw, D.; Brown, J. The peripheral benzodiazepine receptor ligand PK11195 binds with high affinity to the acute phase reactant [alpha]1-acid glycoprotein: implications for the use of the ligand as a CNS inflammatory marker. Nucl. Med. Biol. 2003, 30, 199-206.
109. Boutin, H.; Chauveau, F.; Thominiaux, C.; Gregoire, M.-C.; James, M. L.; Trebossen, R.; Hantraye, P.; Dolle, F.; Tavitian, B.; Kassiou, M. 11C-DPA-713: a novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation. J. Nucl. Med. 2007, 48, 573-581.
110. Maeda, J.; Ji, B.; Irie, T.; Tomiyama, T.; Maruyama, M.; Okauchi, T.; Staufenbiel, M.; Iwata, N.; Ono, M.; Saido, T. C.; Suzuki, K.; Mori, H.; Higuchi, M.; Suhara, T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 2007, 27, 10957-10968.
111. Kassiou, M.; Meikle, S.; Banati, B. Ligands for peripheral benzodiazepine binding sites in glial cells. Brain Res. Rev. 2005, 48, 207-210.
112. Messmer, K.; Reynolds, G. P. Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease. Neurosci. Lett. 1998, 241, 53-56.
113. Chelli, B.; Pini, S.; Abelli, M.; Cardini, A.; Lari, L.; Muti, M.; Gesi, C.; Cassano, G. B.; Lucacchini, A.; Martini, C. Platelet 18 kDa translocator protein density is reduced in depressed patients with adult separation anxiety. Eur. Neuropsychopharmacol. 2008, 18, 249-254. JM8011678